Register status of hypertension research in special Chinese population_Chinese Journal of Evidence-Based Medicine

Authors：

ZHONG Ming ^1,2 , SU Yanling ¹ , GUO Ru ¹ ,  LIAO Xiaoyang ¹

1. Ward of General Practice Unit, International Medical Center, West China Hospital of Sichuan University, Chengdu 610041, P.R.China;
2. Department of Neurology, The Second People's Hospital of Neijiang, Neijiang 641000, P.R.China;

Corresponding author：

LIAO Xiaoyang, Email: 625880796@qq.com

Keywords：

Hypertension; Special population; Clinical trial; Clinical trial registration; Chinese Clinical Trial Registry

DOI：

10.7507/1672-2531.201909086

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To analyze the research status and hot spots of hypertension-related clinical trials in special Chinese population registered on the Chinese Clinical Trial Registry (ChiCTR), so as to provide a basis for the development of hypertension-related research in special population in China.Methods The ChiCTR was searched online (up to August 31^st, 2019, no limitation in the status of trial registration), all clinical trials on hypertension in special population were collected, and the general characteristics, researched diseases, research types, intervention measures and main outcomes of the trials were analyzed.Results A total of 64 hypertension-related clinical trials in special population registered in the ChiCTR were included, including 41 (64.1%) trials registered in last 3 years. The registration status of 46 (71.9%) trials was pre-registration. The registered authors were mainly from colleges and universities or medical institutions (n = 61, 95.3%), of which 60.9% were registered in Beijing, Shanghai, Guangdong, Zhejiang, Jiangsu and Hebei. The researched diseases mainly included elderly hypertension and hypertensive stroke, accounting for 50% of the total. Additionally, 37 (57.8%) clinical trials were intervention studies, of which 21 (56.7%) were drug-based intervention studies. Blood pressure, blood glucose, cardiovascular and cerebrovascular events, blood lipid, cranial MRI and Glasgow Coma Scale were the commonly used outcomes, accounting for 58.5% of the total outcomes. Most blood pressure measurements did not indicate the measurement method (n = 22, 64.7%).Conclusions The quantity of hypertension-related clinical trials in special population registered on the ChiCTR is increasing, however, there exists regional imbalance. The drug intervention-related clinical trials of elderly hypertension have become a research hot spot. However, blood pressure measurement method is not indicated in most trials, and some researchers do not register in time. Therefore, it is suggested that researchers should further strengthen the awareness of carrying out high-quality clinical trials.

Citation： ZHONG Ming, SU Yanling, GUO Ru, LIAO Xiaoyang. Register status of hypertension research in special Chinese population. Chinese Journal of Evidence-Based Medicine, 2020, 20(3): 325-329. doi: 10.7507/1672-2531.201909086 Copy

1.	GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016, 388(10053): 1659-1724.
2.	Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2224-2260.
3.	WHO. Causes of death 2008: data sources and methods. Available at: https://www.who.int/healthinfo/global_burden_disease/cod_2008_sources_methods.pdf.
4.	刘力生. 中国高血压防治指南2010. 中华高血压杂志, 2011, 19(8): 701-743.
5.	Lackland DT, Woolson RF. Clinical hypertension research tools: the randomized controlled clinical trial. J Clin Hypertens (Greenwich), 2006, 8(6): 427-431.
6.	De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Circulation, 2005, 111(10): 1337-1338.
7.	吴泰相, 李幼平, 刘关键, 等. 中国临床试验注册中心及中国循证医学中心提高我国临床试验质量的策略和措施. 中国循证医学杂志, 2010, 10(11): 1243-1248.
8.	中国高血压防治指南修订委员会. 中国高血压防治指南2010. 中华心血管病杂志, 2011, 39(7): 579-616.
9.	吴泰相, 米娜瓦尔·阿不都, 郝园, 等. 中国临床试验注册10年: 现状与问题. 中国循证医学杂志, 2018, 18(6): 522-525.
10.	吴泰相, 李幼平, 刘关键, 等. 临床试验注册制度与循证医学. 中国循证医学杂志, 2007, 7(4): 239-243.
11.	邬兰, 田国祥, 王行环, 等. 临床试验的注册及注册平台比较分析. 中国循证心血管医学杂志, 2017, 9(2): 129-134.
12.	吴泰相, 李幼平, 李静, 等. 中国临床试验注册和发表机制及实施说明. 中国动脉硬化杂志, 2006, 14(7): 639-640.
13.	苏艳玲, 全柳柳, 杨梓钰, 等. 中国临床试验注册中心注册高血压临床试验的特征分析. 中国循证医学杂志, 2018, 18(10): 1114-1117.
14.	李晓晖, 詹思延, 李立明. 随机化临床试验结果分析和解释的几个问题. 中华医学杂志, 2000, 80(6): 74-76.
15.	吴泰相, 李幼平, 卞兆祥, 等. 中医药临床随机对照试验报告规范(征求意见稿). 中国循证医学杂志, 2007, 7(8): 601-605.
16.	全国血压抽样调查协作组. 中国人群高血压患病率及其变化趋势. 高血压杂志, 1995, 3(S1): 9-15.
17.	李苏宁, 陈祚, 王增武, 等. 我国老年人高血压现状分析. 中华高血压杂志, 2019, 27(2): 140-148.
18.	Elliott HL, Meredith PA. Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina. J Hum Hypertens, 2011, 25(1): 63-70.
19.	Zarin DA, Tse T, Williams RJ, et al. Trial reporting in ClinicalTrials.gov - the final rule. N Engl J Med, 2016, 375(20): 1998-2004.

1. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016, 388(10053): 1659-1724.
2. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2224-2260.
3. WHO. Causes of death 2008: data sources and methods. Available at: https://www.who.int/healthinfo/global_burden_disease/cod_2008_sources_methods.pdf.
4. 刘力生. 中国高血压防治指南2010. 中华高血压杂志, 2011, 19(8): 701-743.
5. Lackland DT, Woolson RF. Clinical hypertension research tools: the randomized controlled clinical trial. J Clin Hypertens (Greenwich), 2006, 8(6): 427-431.
6. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Circulation, 2005, 111(10): 1337-1338.
7. 吴泰相, 李幼平, 刘关键, 等. 中国临床试验注册中心及中国循证医学中心提高我国临床试验质量的策略和措施. 中国循证医学杂志, 2010, 10(11): 1243-1248.
8. 中国高血压防治指南修订委员会. 中国高血压防治指南2010. 中华心血管病杂志, 2011, 39(7): 579-616.
9. 吴泰相, 米娜瓦尔·阿不都, 郝园, 等. 中国临床试验注册10年: 现状与问题. 中国循证医学杂志, 2018, 18(6): 522-525.
10. 吴泰相, 李幼平, 刘关键, 等. 临床试验注册制度与循证医学. 中国循证医学杂志, 2007, 7(4): 239-243.
11. 邬兰, 田国祥, 王行环, 等. 临床试验的注册及注册平台比较分析. 中国循证心血管医学杂志, 2017, 9(2): 129-134.
12. 吴泰相, 李幼平, 李静, 等. 中国临床试验注册和发表机制及实施说明. 中国动脉硬化杂志, 2006, 14(7): 639-640.
13. 苏艳玲, 全柳柳, 杨梓钰, 等. 中国临床试验注册中心注册高血压临床试验的特征分析. 中国循证医学杂志, 2018, 18(10): 1114-1117.
14. 李晓晖, 詹思延, 李立明. 随机化临床试验结果分析和解释的几个问题. 中华医学杂志, 2000, 80(6): 74-76.
15. 吴泰相, 李幼平, 卞兆祥, 等. 中医药临床随机对照试验报告规范(征求意见稿). 中国循证医学杂志, 2007, 7(8): 601-605.
16. 全国血压抽样调查协作组. 中国人群高血压患病率及其变化趋势. 高血压杂志, 1995, 3(S1): 9-15.
17. 李苏宁, 陈祚, 王增武, 等. 我国老年人高血压现状分析. 中华高血压杂志, 2019, 27(2): 140-148.
18. Elliott HL, Meredith PA. Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina. J Hum Hypertens, 2011, 25(1): 63-70.
19. Zarin DA, Tse T, Williams RJ, et al. Trial reporting in ClinicalTrials.gov - the final rule. N Engl J Med, 2016, 375(20): 1998-2004.

Chinese Journal of Evidence-Based Medicine

Register status of hypertension research in special Chinese population

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content